Anixa Biosciences, Inc., a biotechnology company focused on using the body’s immune system to fight cancer, today announced it has extended its collaboration with The Wistar Institute and Dmitry I. Gabrilovich, M.D., Ph.D. Gabrilovich is a pioneer in the field of myeloid-derived suppressor cell (MDSC) biology and its roles in cancer progression and therapy response. The project is focused on understanding the role of MDSCs and how they can be used in diagnostic and therapeutic applications.
We are pleased to continue our collaboration with our long-time partner, The Wistar Institute. With support from Wistar and in collaboration with their laboratories and personnel, we have made tremendous progress with our Cchek™ cancer detection technology and in gaining a greater understanding of the role of MDSCs in cancer
stated Amit Kumar, Ph.D.,
President and CEO of Anixa Biosciences.
Our joint project has focused on discovering and validating new markers that can identify MDSCs. We are pleased to be continuing this collaboration with Anixa. Our goal is to continue to understand the behavior of MDSCs, which are now known to play a major role in enabling tumors to evade and escape the immune system,
stated Dmitry I. Gabrilovich, M.D.,
Ph.D., Professor and Leader of the Immunology,
Microenvironment and Metastasis Program at The Wistar Institute.
Anixa has been a wonderful partner of ours for years, and we are looking forward to continuing our fruitful collaboration,
Heather A. Steinman, Ph.D., M.B.A., Vice President
for Business Development and Executive Director
for Technology Transfer at The Wistar Institute stated.